Miami Cancer Institute Highlights Broad Oncology Research Portfolio at 2026 ASCO Annual Meeting
MIAMI, FL& CHICAGO, IL – May 5, 2026 – Miami Cancer Institute, part of Baptist Health South Florida, will showcase a diverse range of research at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 29 – June 2 at McCormick Place in Chicago, Illinois. This year’s presentations span multiple tumor types and research areas, including a rapid oral presentation on authorship trends in phase III oncology trials, as well as research in glioblastoma and brain metastases, lung and gastrointestinal cancers, and prostate malignancies, alongside studies focused on clinical trial access, screening, and outcomes disparities.
“Our research presented at this year’s ASCO Annual Meeting reflects both the depth and diversity of work underway at Miami Cancer Institute,” said Manmeet Singh Ahluwalia, M.D., MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research. “From clinical trials in glioblastoma and brain metastases to advances in lung cancer detection, gastrointestinal malignancies, and prostate cancer outcomes, these studies also address critical questions around clinical trial access and screening gaps. Together, they reflect our commitment to improving outcomes across the cancer continuum.”
Miami Cancer Institute’s presentations at ASCO 2026 include:
Oral Presentation
Friday, May 29, 2026
Gender Representation in First and Senior Authorship of Phase III Solid-Tumor Trials Presented at the ASCO Annual Meeting, 2015-2025
Presenter: Sarbajit Mukherjee, M.D., M.S.
Time: 03:15p.m. – 03:21 p.m. CT
Location: E450b
Abstract: 9006
Panel Discussion
Saturday, May 30, 2026
Double Trouble or Double Benefit? The Toxicity Tradeoffs of Targeted Therapy Immunotherapy Combinations
Panelist: Bruna Pellini, M.D.
Time: 08:00a.m. – 09:30a.m. CT
Location: Arie Crown Theater
Poster Presentations
Saturday, May 30, 2026
Clinical trial participation among adolescents and young adults diagnosed with cancer in the United States (2004-2021)
Presenter: Fatma Nihan Akkoc Mustafayev, M.D.
Time: 09:00a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 310
Who Gets Access? National Discrepancies in Clinical Trial Enrollment Among Patients with Brain Metastases
Presenter: Zouina Sarfraz, MBBS
Time: 09:00a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 573
Neoadjuvant chemokine modulation of the tumor microenvironment (TME) in resectable metastatic colorectal cancer: Results from a phase I study
Presenter: Sarbajit Mukherjee, M.D., M.S.
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 396
Sunday, May 31, 2026
Clinical outcomes of sequential androgen receptor pathway inhibitors (ARPIs) versus novel therapies in metastatic castration-resistant prostate cancer after progression on second-generation ARPIs: A systematic review and meta-analysis
Presenter: Rohan Garje, M.D.
Time: 09:00a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 170
Prognostic value of PSA nadir ≤0.2 ng/mL in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis
Presenter: Arjun Pon Avudaiappan, MBBS, MS, MCh (Uro)
Time: 09:00a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 195
SWOG S2414 (INSIGHT): A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early-Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting
Presenter: Bruna Pellini, M.D.
Time: 09:00a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 601a
Monday, June 1, 2026
Diagnostic accuracy of blood-based cfDNA fragmentomic assays for lung cancer detection: A meta-analysis of clinically validated cohorts
Presenter: Khalid Ahmad Qidwai, MBBS
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 538
Missed by the guidelines: A meta-analysis of USPSTF lung cancer screening ineligibility among patients diagnosed with lung cancer
Presenter: Khalid Ahmad Qidwai, MBBS
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 534
Multimodal risk phenotyping of early-onset colorectal cancer
Presenter: Azza Sarfraz, MBBS
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 522
Phase I trial of trastuzumab deruxtecan in combination with stereotactic radiosurgery for brain metastases from HER2-positive breast cancer
Presenter: Zouina Sarfraz, MBBS
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 457b
Prospective, Randomized, Placebo-Controlled Phase 2b Trial of SurVaxM Plus Adjuvant Temozolomide in Newly Diagnosed Glioblastoma (SURVIVE)
Presenter: Manmeet Singh Ahluwalia, MD, MBA, FASCO
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 464a
Randomized Phase 2 Trial of Ruxolitinib in Combination with Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Presenter: Manmeet Singh Ahluwalia, MD, MBA, FASCO
Time: 01:30p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 458a
For updates from the 2026ASCO Annual Meeting, look for #ASCO26 on social mediaand follow Miami Cancer Institute on X at @MiamiCancerInst.
About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://cancer.baptisthealth.net/miami-cancer-institute.
Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.
###
